There Is More to Length of Survival Than Survival: Endpoints in Oncology Trials.
Clin Cancer Res
; 30(15): 3098-3099, 2024 Aug 01.
Article
in En
| MEDLINE
| ID: mdl-38767553
ABSTRACT
Progression-free survival as a primary endpoint for comparative trials does not fully capture the therapeutic risk/benefit ratio. Additionally, summarization of the treatment effect via a hazard ratio is problematic when the proportional hazards assumption is violated. Restricted mean survival time metrics may address these challenges but have other limitations. See related article by Chang et al., p. 3282.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Clinical Trials as Topic
/
Neoplasms
Limits:
Humans
Language:
En
Journal:
Clin Cancer Res
Journal subject:
NEOPLASIAS
Year:
2024
Document type:
Article